1. American Diabetes Association. Standards of medical care in diabetes : 2013. Diabetes Care 2013; 36 (suppl 1) : S11–66.
2. HAS. Recommandation sur la stratégie du contrôle glycémique du diabète de type 2.
3. Roussel R, Travert F, Pasquet B et al and the Reduction of Atherothrombosis for Continued Health (REACH) registry investigators. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med 2010;170:1892.99.
4. Boussageon R, Supper I, Bejan-Angoulvant T et al. Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. PLoS Med 2012;9(4):e1001204.
5. Protti A, Lecchi A, Fortunato F et al. Metformin overdose causes platelet mitochondrial dysfunction in humans. Crit Care 2012;16: R180.
6. Ekström N, Schiöler L, Svensson AM et al. Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register. BMJ Open 2012; 2: e001076.
En 5 points
Obésité : suivi d’un patient sous aGLP-1
Cas clinique
La fasciite nécrosante
Mise au point
La périménopause
Mise au point
La sclérose en plaques